Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients

Tong NK 1 , Beran J , Kee SA , Miguel JL , Sánchez C , Bayas JM Show all authors , Vilella A , de Juanes JR , Arrazola P , Calbo-Torrecillas F , de Novales EL , Hamtiaux V , Lievens M , Stoffel M

Affiliations 

  • 1 National University Hospital of Malaysia, Kuala Lumpur
Kidney Int, 2005 Nov;68(5):2298-303.
PMID: 16221232

Abstract

Due to their impaired immune system, patients with renal insufficiency have a suboptimal response to hepatitis B (HB) vaccination and frequent boosters are needed to maintain protection. GlaxoSmithKline Biologicals has developed a HB vaccine containing a new adjuvant system AS04 for use in this immunocompromised patient population.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications